


## ERRATA

### 1:Paper III





#### **1:1 This reference list replaces the previous reference list in paper III.**

- D. Chen *et al.*, Molecular determinants of resistance to antiandrogen therapy. *Nat Med* **10**, 33 (Jan, 2004).
- G. Attard *et al.*, Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. *J Clin Oncol* **27**, 3742 (Aug 10, 2009).
- A. Sharma *et al.*, The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. *J Clin Invest* **120**, 4478 (Dec, 2010).
- J. M. Lucas *et al.*, The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis. *Cancer Discov*, (Aug 13, 2014).
- J. F. Goodwin *et al.*, A hormone-DNA repair circuit governs the response to genotoxic insult. *Cancer Discov* **3**, 1254 (Nov, 2013).
- W. R. Polkinghorn *et al.*, Androgen receptor signaling regulates DNA repair in prostate cancers. *Cancer Discov* **3**, 1245 (Nov, 2013).
- F. L. Al-Ubaidi *et al.*, Castration therapy results in decreased Ku70 levels in prostate cancer. *Clin Cancer Res* **19**, 1547 (Mar 15, 2013).
- D. Robinson *et al.*, Integrative clinical genomics of advanced prostate cancer. *Cell* **161**, 1215 (May 21, 2015).
- T. Helleday, The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. *Mol Oncol* **5**, 387 (Aug, 2011).
- H. E. Bryant *et al.*, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* **434**, 913 (Apr 14, 2005).
- H. Farmer *et al.*, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* **434**, 917 (Apr 14, 2005).
- D. J. VanderWeele, G. P. Paner, G. F. Fleming, R. Z. Szmulewitz, Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report. *Front Oncol* **5**, 169 (2015).
- J. Mateo *et al.*, Antitumour Activity of the Parp Inhibitor Olaparib in Unselected Sporadic Castration-Resistant Prostate Cancer (Crpc) in the Toparp Trial. *Annals of Oncology* **25**, (Sep, 2014).
- A. V. D'Amico, M. H. Chen, A. A. Renshaw, M. Loffredo, P. W. Kantoff, Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. *Jama* **299**, 289 (Jan 23, 2008).
- M. D. Mason *et al.*, Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. *J Clin Oncol*, (Feb 17, 2015).
- P. Gottipati *et al.*, Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. *Cancer Res* **70**, 5389 (Jul 1, 2010).
- H. E. Bryant *et al.*, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* **434**, 913 (Apr 14, 2005).
- C. E. Strom *et al.*, Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. *Nucleic Acids Res* **39**, 3166 (Apr, 2011).
- E. M. Rosen, S. Fan, C. Isaacs, BRCA1 in hormonal carcinogenesis: basic and clinical research. *Endocr Relat Cancer* **12**, 533 (Sep, 2005).
- M. D. Nyquist *et al.*, TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. *Proc Natl Acad Sci U S A* **110**, 17492 (Oct 22, 2013).

1:2 Fig 3B (paper III); PC3 (AR-) replaces PCR (AR-)



1:3 Clarification of text characters in Supplementary figure 4 (Paper III)



## 2: Paper IV

The reference number 10 in the reference list is irrelevant and should be discarded.

10. M. J. Schiewer et al., *Cancer Discov* **2**, 1134 (Dec, 2012).